Metformin Use in Diabetes Prior to Hospitalization: Effects on Mortality in Covid-19

      Abstract

      Objective: Although type 2 diabetes mellitus (T2DM) has been reported as a risk factor for coronavirus disease 2019 (COVID-19), the effect of pharmacologic agents used to treat T2DM, such as metformin, on COVID-19 outcomes remains unclear. Metformin increases the expression of angiotensin converting enzyme 2, a known receptor for severe acute respiratory syndrome coronavirus 2. Data from people with T2DM hospitalized for COVID-19 were used to test the hypothesis that metformin use is associated with improved survival in this population.
      Methods: Retrospective analyses were performed on de-identified clinical data from a major hospital in Wuhan, China, that included patients with T2DM hospitalized for COVID-19 during the recent epidemic. One hundred and thirty-one patients diagnosed with COVID-19 and T2DM were used in this study. The primary outcome was mortality. Demographic, clinical characteristics, laboratory data, diabetes medications, and respiratory therapy data were also included in the analysis.
      Results: Of these 131 patients, 37 used metformin with or without other antidiabetes medications. Among the 37 metformin-taking patients, 35 (94.6%) survived and 2 (5.4%) did not survive. The mortality rates in the metformin-taking group versus the non-metformin group were 5.4% (2/37) versus 22.3% (21/94). Using multivariate analysis, metformin was found to be an independent predictor of survival in this cohort (P = .02).
      Conclusion: This study reveals a significant association between metformin use and survival in people with T2DM diagnosed with COVID-19. These clinical data are consistent with potential benefits of the use of metformin for COVID-19 patients with T2DM.
      To read this article in full you will need to make a payment
      AACE Member Login
      AACE Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Berlin D.A.
        • Gulick R.M.
        • Martinez F.J.
        Severe Covid-19.
        N Engl J Med. 2020;
        • McCowen K.
        • Malhotra A.
        • Bistrian B.
        Stress induced hyperglycemia.
        Crit Care Clin. 2001; 17: 107-124
        • Malhotra A.
        Intensive insulin in intensive care.
        N Engl J Med. 2006; 354: 516-518
        • Kavanagh B.P.
        • McCowen K.C.
        Clinical practice. Glycemic control in the ICU.
        N Engl J Med. 2010; 363: 2540-2546
        • Zhu L.
        • She Z.G.
        • Cheng X.
        Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes.
        Cell Metab. 2020; 31: 1068-1077
        • Guo W.
        • Li M.
        • Dong Y.
        Diabetes is a risk factor for the progression and prognosis of COVID-19.
        Diabetes Metab Res Rev. 2020; : e3319
        • Fang L.
        • Karakiulakis G.
        • Roth M.
        Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?.
        Lancet Respir Med. 2020; 8: e21
        • El Messaoudi S.
        • Rongen G.A.
        • de Boer R.A.
        • Riksen N.P.
        The cardioprotective effects of metformin.
        Curr Opin Lipidol. 2011; 22: 445-453
        • Li Y.
        • Liu L.
        • Wang B.
        • Wang J.
        • Chen D.
        Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
        Biomed Rep. 2013; 1: 57-64
        • Pernicova I.
        • Korbonits M.
        Metformin--mode of action and clinical implications for diabetes and cancer.
        Nat Rev Endocrinol. 2014; 10: 143-156
        • Tsakiris A.G.
        • Donald D.E.
        • Rutishauser W.J.
        • Banchero N.
        • Wood E.H.
        Cardiovascular responses to hypertension and hypotension in dogs with denervated hearts.
        J Appl Physiol. 1969; 27: 817-821
        • Garcia E.Y.
        Flumamine, a new synthetic analgesic and anti-flu drug.
        J Philipp Med Assoc. 1950; 26: 287-293
        • Zhang J.
        • Dong J.
        • Martin M.
        AMP-activated protein kinase phosphorylation of angiotensin-converting enzyme 2 in endothelium mitigates pulmonary hypertension.
        Am J Respir Crit Care Med. 2018; 198: 509-520
        • Lan J.
        • Ge J.
        • Yu J.
        Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.
        Nature. 2020; 581: 215-220
        • Bergmark B.A.
        • Bhatt D.L.
        • McGuire D.K.
        Metformin use and clinical outcomes among patients with diabetes mellitus with or without heart failure or kidney dysfunction: observations from the SAVOR-TIMI 53 trial.
        Circulation. 2019; 140: 1004-1014
        • Venter M.
        • Richter K.
        Towards effective diagnostic assays for COVID-19: a review.
        J Clin Pathol. 2020; 73: 370-377
        • Gabir M.M.
        • Hanson R.L.
        • Dabelea D.
        Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes.
        Diabetes Care. 2000; 23: 1113-1118
        • Wu C.
        • Chen X.
        • Cai Y.
        Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.
        JAMA Intern Med. 2020; 180: 934-943
        • Malhotra A.
        • Hepokoski M.
        • McCowen K.
        • Shyy J.Y.
        ACE2, metformin and COVID-19.
        iScience. 2020; 23: 101425
        • Norrie J.D.
        Remdesivir for COVID-19: challenges of underpowered studies.
        Lancet. 2020; 395: 1525-1527
        • Wang Y.
        • Zhang D.
        • Du G.
        Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
        Lancet. 2020; 395: 1569-1578
        • Beigel J.H.
        • Tomashek K.M.
        • Dodd L.E.
        Remdesivir for the treatment of Covid-19 - preliminary report.
        N Engl J Med. 2020; : 2007764
        • Geleris J.
        • Sun Y.
        • Platt J.
        Observational study of hydroxychloroquine in hospitalized patients with Covid-19.
        N Engl J Med. 2020; 382: 2411-2418
        • Rosenberg E.S.
        • Dufort E.M.
        • Udo T.
        Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State.
        JAMA. 2020; 323: 2493-2502
        • Ramnath V.R.
        • McSharry D.G.
        • Malhotra A.
        Do no harm: reaffirming the value of evidence and equipoise while minimizing cognitive bias in the COVID-19 era.
        Chest. 2020; 158: 873-876
        • Xu X.
        • Han M.
        • Li T.
        Effective treatment of severe COVID-19 patients with tocilizumab.
        Proc Natl Acad Sci U S A. 2020; 117: 10970-10975
        • Jarcho J.A.
        • Ingelfinger J.R.
        • Hamel M.B.
        • D’Agostino Sr, R.B.
        • Harrington D.P.
        Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19.
        N Engl J Med. 2020; 382: 2462-2464
        • Schädle P.
        • Tschritter O.
        • Kellerer M.
        Metformin associated lactic acidosis in clinical practice - a case series.
        Exp Clin Endocrinol Diabetes. 2020;
        • Ursini F.
        • Ciaffi J.
        • Landini M.P.
        • Meliconi R.
        COVID-19 and diabetes: is metformin a friend or foe?.
        Diabetes Res Clin Pract. 2020; 164: 108167
        • Vaduganathan M.
        • Vardeny O.
        • Michel T.
        • McMurray Jjv
        • Pfeffer M.A.
        • Solomon S.D.
        Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19.
        N Engl J Med. 2020; 382: 1653-1659
        • Patel A.B.
        • Verma A.
        COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence?.
        JAMA. 2020; 323: 1769-1770
        • Bramante C.
        • Ingraham N.
        • Murray T.
        Observational study of metformin and risk of mortality in Patients Hospitalized with Covid-19.
        medRxiv. 2020;
        • Luo P.
        • Qiu L.
        • Liu Y.
        Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis.
        Am J Trop Med Hyg. 2020; 103: 69-72